Key pathways as therapeutic targets

Abstract

Somatic mutations are important factors in tumorigenesis. In this issue of Blood, Zhang et al have identified recurrent mutations in key signaling pathways in highrisk childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) to be exploited in the development of new therapeutic approaches.